Tag: NSCLC,Press Releases,Veristrat,blood-based cancer test,cancer diagnostics,financing,liquid biopsy,mutation test

Biodesix, Inc., a molecular diagnostics company that develops and commercializes blood-based tests in oncology enabling physicians to make more precise diagnostic and therapeutic decisions, announced today that the company increased the size of its offering of series E preferred shares in a follow-on sale. In addition to the $15 million of series E shares sold…